GLP1R and Parkinson disease: In agreement with this is the fact that the neuroprotective potential of a glucagon‐like peptide‐1 (GLP‐1) receptor agonist, which significantly increased pathological α‐synuclein load in an animal model of α‐synucleinopathy [43], has recently been shown to be a possible disease‐modifying treatment in PD patients [44].